Furthermore, SBI-477, an inhibitory molecule of this factor also reduces intramuscular fat and improves insulin signaling, suggesting that MondoA could be a potential therapeutic target in T2DM [138]. The gene discussed is INS; the disease is type 2 diabetes mellitus.